( March 28, 2025, 9:11 AM EDT) -- WASHINGTON, D. C. — A Federal Circuit U. S. Court of Appeals panel held that the U. S. Court of Federal Claims did not err when it held that a generic drugmaker could deduct costs it incurred while defending itself from patent claims under the Hatch-Waxman Act as ordinary business expenses, rejecting arguments made on appeal by the federal government. . . .